Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Dulai, Parambir S., Singh, Siddharth, Patel, Janki, Soni, Meera, Prokop, Larry J., Younossi, Zobair, Sebastiani, Giada, Ekstedt, Mattias, Hagstrom, Hannes, Nasr, Patrik, Stal, Per, Wong, Vincent Wai‐Sun, Kechagias, Stergios, Hultcrantz, Rolf, Loomba, Rohit·2017·Hepatology
DOI 10.1002/hep.29085

Cited by (1,004)

Items 1,001–1,004 of 1,004

  1. The effect of intermittent fasting diet in comparison with low-calorie diet on inflammation, lipid profile, glycemic index, liver fibrosis in patients with metabolic-associated fatty liver disease (MAFLD): a randomized controlled trial
    Karimi, Mehdi, Akhgarjand, Camellia, Houjaghani, Hirad, Nejad, Maryam Mofidi, Sohrabpour, Amir Ali, Poustchi, Hossein, Mohammadi, Hamed, Chamari, Maryam, Imani, Hossein · 2025 · Clinical Therapeutics
  2. The methyltransferase MLL4 promotes nonalcoholic steatohepatitis by enhancing NF-κB signaling
    Lee, Junekyoung, An, Hyejin, Kim, Chong-Su, Lee, Seunghee · 2024 · Journal of Biological Chemistry
  3. The double-edged sword of regulatory T cells in MASLD: from inflammation control to fibrosis promotion
    Lee, So Eun, Jo, Min Gi, Park, Sang Won, Kim, Hye Jung, Yun, Seung Pil, Kim, Jong-Won · 2026 · Animal Cells and Systems
  4. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
    Takahashi, Hirokazu, Kessoku, Takaomi, Kawanaka, Miwa, Nonaka, Michihiro, Hyogo, Hideyuki, Fujii, Hideki, Nakajima, Tomoaki, Imajo, Kento, Tanaka, Kenichi, Kubotsu, Yoshihito et al. · 2025 · Diabetes mellitus